C71T
CANCELLED SECTION 71
01/23/2026
Back to search
Official data from USPTO
PARCLYA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
02/17/2026
Trademark type
Word
Nice classes
5
Filing date
12/24/2018
Registration date
07/09/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/23/2026
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
CHOSID, ROBIN S
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Novartis AG
Representatives
Novartis Pharma AG, Trademark Department
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
16 publications found
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
01/25/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/22/2020
GPNX
NOTIFICATION PROCESSED BY IB
09/19/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/31/2019
FIMP
FINAL DISPOSITION PROCESSED
08/31/2019
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
08/08/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2019
PUBO
PUBLISHED FOR OPPOSITION
04/23/2019
NPUB
NOTICE OF PUBLICATION
04/03/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/11/2019
DOCK
ASSIGNED TO EXAMINER
03/10/2019
MAFR
APPLICATION FILING RECEIPT MAILED
03/02/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/26/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
02/25/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/21/2019
Continuous trademark protection
Get notified about every new filing that threatens PARCLYA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.